SCHEMBL3439836

SCHEMBL3439836

CN(C)CCCCNc1ccnc(Nc2cccc(Cl)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 4/20 0.56
CDK4 P11802 3/20 0.56
CDK2 P24941 3/20 0.56
MAPT P10636 3/20 0.56
MAPK1 P28482 3/20 0.56
CDK5 Q00535 3/20 0.56
CDK5R1 Q15078 3/20 0.56
CCNB1 P14635 2/20 0.56
CCNA2 P20248 2/20 0.56
CCND1 P24385 2/20 0.56
CDK7 P50613 2/20 0.56
CCNH P51946 2/20 0.56
NPC1 O15118 2/20 0.56
XBP1 P17861 2/20 0.56
HTT P42858 2/20 0.56
RAB9A P51151 2/20 0.56
CCNT1 O60563 1/20 0.56
CCNE1 P24864 1/20 0.56
MTOR P42345 1/20 0.56
CDK9 P50750 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3439824 0.98 CDK1 (0.59) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL3439820 0.83 MAP3K5 (0.56) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL3977425 0.80 CDK1 (0.54) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL3439821 0.80 MAP3K5 (0.50) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL3613529 0.79 MAPT (0.54) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL14293084 0.79 IGF1R (0.56) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL14380911 0.79 IGF1R (0.74) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL13698056 0.77 KDR (0.59) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL3439822 0.77 HTT (0.46) CDK1CDK4CDK2MAPTMAPK1
SCHEMBL3950905 0.76 KDR (0.59) CDK4CDK2KDRIGF1RCAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158641-B2 2-anilino-4-aminoalkyleneaminopyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-17 US disclosed
US-8158641-B2 2-anilino-4-aminoalkyleneaminopyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-17 US disclosed
US-20090181995-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-16 US disclosed
US-20090181995-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-16 US disclosed
US-20070293525-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-20 US disclosed
US-20070293525-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293525-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES PRKCA, PRKCH, PRKCG CDK1 173/4885CDK4 337/4885CDK2 69/4885
US-20090181995-A1 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES PRKCA, PRKCH, PRKCG CDK1 173/4885CDK4 337/4885CDK2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.